Friday, 25 September 2026European Markets

NYRSTAR Stock Went Up By Over 24% In The Last 10 Sessions

Loading stream...

(VIANEWS) - Shares of NYRSTAR (BEL 20: NYR.BR) rose by a staggering 24.03% in 10 sessions from €0.13 to €0.16 at 14:22 EST on Tuesday, after four successive sessions in a row of gains. BEL 20 is jumping 0.64% to €3,529.65, after two consecutive sessions in a row of gains.

NYRSTAR's last close was €0.16, 36.35% under its 52-week high of €0.25.

About NYRSTAR

Nyrstar NV does not have significant operations. Previously, it was engaged in the mining, smelting, and producing of zinc, lead, and other base and precious metals primarily in Europe, Australia, Canada, and the United States. Nyrstar NV was founded in 2007 and is based in Balen, Belgium.

Earnings Per Share

As for profitability, NYRSTAR has a trailing twelve months EPS of €-0.01.

Volatility

NYRSTAR's last week, last month's, and last quarter's current intraday variation average was 5.51%, 1.58%, and 2.91%.

NYRSTAR's highest amplitude of average volatility was 5.51% (last week), 2.59% (last month), and 2.91% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NYRSTAR's stock is considered to be oversold (<=20).

More news about NYRSTAR (NYR.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Scale Up Through Partnerships and Funding, But Data Readiness Lags Ambition
A wave of vertical AI-agent startups (Swarm, Veridox, Avallon AI, DA2, F2, Earthian, Meanwhile, Covecta, Penguin AI, Maisa AI) is being funded and profiled just as major infrastructure players — Microsoft/Mistral, Siemens/NVIDIA, and Manulife/Microsoft — cement enterprise AI governance and compute partnerships. Yet a Google Cloud report shows AI agents still lack access to the majority of company data (only 45% on average), and insider selling at incumbent C3.ai signals investor caution even as adoption intent (100% planned agentic AI use within two years) races ahead of actual data infrastructure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com